101 related articles for article (PubMed ID: 34313338)
1. Histopathological and molecular profiling of lung adenocarcinoma skin metastases reveals specific features.
Forest F; Laville D; Habougit C; Da Cruz V; Casteillo F; Yvorel V; Bard-Sorel S; Godard W; Picot T; Tiffet O; Perrot JL; Péoc'h M
Histopathology; 2021 Dec; 79(6):1051-1060. PubMed ID: 34313338
[TBL] [Abstract][Full Text] [Related]
2. Association of Lung Adenocarcinoma Subtypes According to the IASLC/ATS/ERS Classification and Programmed Cell Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Cruz-Rico G; Avilés-Salas A; Popa-Navarro X; Lara-Mejía L; Catalán R; Sánchez-Reyes R; López-Sánchez D; Cabrera-Miranda L; Aquiles Maldonado-Martínez H; Samtani-Bassarmal S; Arrieta O
Pathol Oncol Res; 2021; 27():597499. PubMed ID: 34257548
[No Abstract] [Full Text] [Related]
3. Differential molecular markers of primary lung tumors and metastatic sites indicate different possible treatment selections in patients with metastatic lung adenocarcinoma.
Deng LL; Deng HB; Lu CL; Gao G; Wang F; Yang Y
Clin Transl Oncol; 2019 Feb; 21(2):197-205. PubMed ID: 29948972
[TBL] [Abstract][Full Text] [Related]
4. Programmed death ligand 1 protein expression is positively correlated with the solid predominant subtype, high MIB-1 labeling index, and p53 expression and negatively correlated with epidermal growth factor receptor mutations in lung adenocarcinoma.
Yanagawa N; Shiono S; Endo M; Ogata SY; Yamada N; Sugimoto R; Osakabe M; Uesugi N; Sugai T
Hum Pathol; 2021 Feb; 108():12-21. PubMed ID: 33159965
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma.
Deng C; Zhang Y; Ma Z; Fu F; Deng L; Li Y; Chen H
J Thorac Cardiovasc Surg; 2021 Sep; 162(3):664-674.e7. PubMed ID: 32747123
[TBL] [Abstract][Full Text] [Related]
6. Molecular genetic alterations in thyroid transcription factor 1-negative lung adenocarcinoma in cytology specimens: A subset with aggressive behavior and a poor prognosis.
Rodriguez EF; VandenBussche CJ; Chowsilpa S; Maleki Z
Cancer Cytopathol; 2018 Oct; 126(10):853-859. PubMed ID: 30199148
[TBL] [Abstract][Full Text] [Related]
7. [Relevance of molecular alterations in histopathologic subtyping of lung adenocarcinoma based on 2011 International Multidisciplinary Lung Adenocarcinoma Classification].
Liu B; Shi SS; Wang X; Xu Y; Zhang XH; Yu B; Lu ZF; Wang JD; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2012 Aug; 41(8):505-10. PubMed ID: 23157740
[TBL] [Abstract][Full Text] [Related]
8. Molecular diagnostic characteristics based on the next generation sequencing in lung cancer and its relationship with the expression of PD-L1.
Liu J; Liu Y
Pathol Res Pract; 2020 Feb; 216(2):152797. PubMed ID: 31926773
[TBL] [Abstract][Full Text] [Related]
9. Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations.
Toki MI; Mani N; Smithy JW; Liu Y; Altan M; Wasserman B; Tuktamyshov R; Schalper K; Syrigos KN; Rimm DL
J Thorac Oncol; 2018 Dec; 13(12):1884-1896. PubMed ID: 30267840
[TBL] [Abstract][Full Text] [Related]
10. Next generation sequencing of lung adenocarcinoma subtypes with intestinal differentiation reveals distinct molecular signatures associated with histomorphology and therapeutic options.
Jurmeister P; Vollbrecht C; Behnke A; Frost N; Arnold A; Treue D; Rückert JC; Neudecker J; Schweizer L; Klauschen F; Horst D; Hummel M; Dietel M; von Laffert M
Lung Cancer; 2019 Dec; 138():43-51. PubMed ID: 31634654
[TBL] [Abstract][Full Text] [Related]
11. EGFR mutation status in primary lung adenocarcinomas and corresponding metastatic lesions: discordance in pleural metastases.
Han HS; Eom DW; Kim JH; Kim KH; Shin HM; An JY; Lee KM; Choe KH; Lee KH; Kim ST; Koo JH; Lee HC; Lee OJ
Clin Lung Cancer; 2011 Nov; 12(6):380-6. PubMed ID: 21729655
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
Tao L; Miao R; Mekhail T; Sun J; Meng L; Fang C; Guan J; Jain A; Du Y; Allen A; Rzeszutko BL; Socinski MA; Chang CC
Clin Lung Cancer; 2021 Jul; 22(4):e506-e511. PubMed ID: 32807653
[TBL] [Abstract][Full Text] [Related]
13. Programmed cell death-ligand 1 (PD-L1) expression is associated with RAS/TP53 mutations in lung adenocarcinoma.
Serra P; Petat A; Maury JM; Thivolet-Bejui F; Chalabreysse L; Barritault M; Ebran N; Milano G; Girard N; Brevet M
Lung Cancer; 2018 Apr; 118():62-68. PubMed ID: 29572005
[TBL] [Abstract][Full Text] [Related]
14. Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment.
Huynh TG; Morales-Oyarvide V; Campo MJ; Gainor JF; Bozkurtlar E; Uruga H; Zhao L; Gomez-Caraballo M; Hata AN; Mark EJ; Lanuti M; Engelman JA; Mino-Kenudson M
J Thorac Oncol; 2016 Nov; 11(11):1869-1878. PubMed ID: 27568346
[TBL] [Abstract][Full Text] [Related]
15. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
[TBL] [Abstract][Full Text] [Related]
16. Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.
Gupta R; Amanam I; Rahmanuddin S; Mambetsariev I; Wang Y; Huang C; Reckamp K; Vora L; Salgia R
Am J Clin Oncol; 2019 Apr; 42(4):337-344. PubMed ID: 30741758
[TBL] [Abstract][Full Text] [Related]
17. Exploring the spatiotemporal genetic heterogeneity in metastatic lung adenocarcinoma using a nuclei flow-sorting approach.
Lorber T; Andor N; Dietsche T; Perrina V; Juskevicius D; Pereira K; Greer SU; Krause A; Müller DC; Savic Prince S; Lardinois D; Barrett MT; Ruiz C; Bubendorf L
J Pathol; 2019 Feb; 247(2):199-213. PubMed ID: 30350422
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor mutation status in pulmonary adenocarcinoma: Multi-institutional data discussion at national conference of "Lung Cancer Management in Indian context".
Nakra T; Mehta A; Bal A; Nambirajan A; Mishra D; Midha D; Gupta N; Arora N; Gupta P; Gupta P; Singh V; Jain D
Curr Probl Cancer; 2020 Jun; 44(3):100561. PubMed ID: 32169258
[TBL] [Abstract][Full Text] [Related]
19. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors.
Yang CY; Liao WY; Ho CC; Chen KY; Tsai TH; Hsu CL; Su KY; Chang YL; Wu CT; Hsu CC; Liao BC; Hsu WH; Lee JH; Lin CC; Shih JY; Yang JC; Yu CJ
Eur J Cancer; 2020 Jan; 124():110-122. PubMed ID: 31760310
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of PD-L1 expression in lung adenocarcinoma metastasis is related to histopathological subtypes.
Forest F; Casteillo F; Da Cruz V; Yvorel V; Picot T; Vassal F; Tiffet O; Péoc'h M
Lung Cancer; 2021 May; 155():1-9. PubMed ID: 33690015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
